INAB
IN8bio Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
in8bio, inc. (“in8bio”) is a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancers by employing allogeneic, autologous and genetically modified gamma-delta t cells. we are developing a broad portfolio of programs and are the first company to advance genetically modified gamma-delta t cells into the clinic.
Market Cap: 49.8 Million
Primary Exchange: NASDAQ
Website: https://www.in8bio.com
Shares Outstanding: 43.3 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.5343647109985581
Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Ethical Flags
Longest drawdown: 823 trading days
From: 2021-08-02 To: 2024-03-07
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|